紅牆股份(002809.SZ):副董事長盧峯增持6.055萬股
格隆匯5月13日丨紅牆股份(002809.SZ)公佈,副董事長盧峯擬以自有資金於2020年3月2日通過集中競價交易方式增持公司股份共計2.735萬股,佔公司總股本的0.0228%,增持成交金額為47.11萬元;並自2020年3月2日起未來6個月內(即2020年3月2日至2020年9月1日),擬通過集中競價交易和大宗交易的方式繼續增持公司股份,增持金額不低於人民幣100萬元,不高於人民幣300萬元(含上述已增持金額47.11萬元)。
截止2020年5月13日,盧峯累計增持股份6.055萬股,佔公司總股本的0.0505%,增持成交金額為105.10萬元,超過增持金額區間下限的100%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.